Darolutamide (Nubeqa®) in Combination with Docetaxel (Taxotere®) for Metastatic Hormone Sensitive Prostate Cancer

In an effort to promote higher quality patient care NCODA created the NCODA Positive Quality Intervention (PQI) as a peer-reviewed clinical guidance resource for healthcare providers. By providing Quality Standards and effective practices around a specific aspect of cancer care, PQIs equip the entire multidisciplinary care team with a sophisticated yet concise resource for managing patients receiving oral or IV oncolytics. This PQI in Action is a follow up to the Darolutamide (NUBEQA®) in Combination with Docetaxel (TAXOTERE®) for Metastatic Hormone Sensitive Prostate Cancer PQI and explores how the medically integrated teams at Illinois CancerCare and Arizona Blood and Cancer Specialists incorporate the information found in the PQIs as part of their daily workflow. This article will discuss how utilizing the Darolutamide (NUBEQA®) in Combination with Docetaxel (TAXOTERE®) for Metastatic Hormone Sensitive Prostate Cancer PQI elevates patient care.